Table 2.

Antibody response by GMCs, geometric mean ratios and response rates in multiple myeloma and myeloproliferative malignancies in comparison with elderly controls.

	Multiple myeloma (n = 42)	Myeloproliferative malignancy (n = 50)	Elderly controls (n = 36)
TP0 day 0 (1st dose)
GMC (95% CI), AU/mL	4.2 (3.9–4.6)	4.6 (4.2–5.2)	3.8 (3.8–3.8)
TP1 day 21 (2nd dose)
GMC (95% CI), AU/mL [p]	7.5 (5.6–10.4) [p < 0.001]	16.2 (11.7–22.3) [p = 0.837]	17.1 (12.0–24.1)
Seroconversion rate (i.e., responders), n (%) [p]	9 (21.4) [p = 0.005]	26 (52.0) [p = 1]	19 (52.8)
TP2 day 35
GMC (95% CI), AU/mL [p]	106.7 (62.3–179.7) [p = 0.003]	172.9 (106.5–257.0) [p = 0.049]	353.3 (255.6–470.0)
GM ratio (TP2-GMC/TP1-GMC) (95% CI) [p]	13.1 (8.2–21.1) [p = 0.288]	10.0 (7.1–13.4) [p = 0.015]	19.7 (13.5–28.4)
Seroconversion rate (i.e., responders), n (%) [p]	33 (78.6) [p = 0.003]	44 (88.0) [p = 0.038]	36 (100)

GMC, geometric mean concentration (95% confidence interval); TP, time point.